Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
We are a global, commercial-stage biopharmaceutical company, focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. We are committed to the principles of precision oncology. By this we mean developing both therapeutic and diagnostic modalities for the benefit of patients, an innovative precision medicine concept generally referred to as ‘theranostics’.
In the company’s own words · 20-F filed Feb 20, 2026 · SEC EDGAR
For the full year FY2025, revenue was $804M (+56% year on year) and net income −$7.1M.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Biotechnology
The closest names by size in the same industry